26/07/2016 23:45:06 1-888-992-3836 (toll free) Free Membership Login

Mylan N.V. News (NASDAQ:MYL)

DateTimeSource
Headline
07/21/20161:00PMPRNUSMylan Publishes Supplement to Meda Offer Document
Mylan Publishes Supplement to Meda Offer Document PR Newswire HERTFORDSHIRE, England, and PITTSBURGH, July 21, 2016 HERTFORDSHIRE, England, and PITTSBURGH, July 21, 2016 /PRNewswire/ -- The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of... More...>>
07/21/20161:00PMPRNUSMylan Publishes Supplement to Meda Offer Document
Mylan Publishes Supplement to Meda Offer Document PR Newswire HERTFORDSHIRE, England, and PITTSBURGH, July 21, 2016 HERTFORDSHIRE, England, and PITTSBURGH, July 21, 2016 /PRNewswire/ -- The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of... More...>>
07/21/201610:00AMPRNUSMylan and Biocon Announce Regulatory Submission for Proposed Biosimilar Pegfilgrastim Accepted for Review by European Medicin...
Mylan and Biocon Announce Regulatory Submission for Proposed Biosimilar Pegfilgrastim Accepted for Review by European Medicines Agency PR Newswire BENGALURU, India, HERTFORDSHIRE, England and PITTSBURGH, July 21, 2016 BENGALURU, India, HERTFORDSHIRE, England and PITTSBURGH, July 21, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ... More...>>
07/20/201612:20PMDJNEU Approves Mylan's $7.2 Billion Acquisition of Meda
BRUSSELS—European Union competition regulators on Wednesday approved Dutch drugmaker Mylan NV's roughly $7.2 billion acquisition of its Swedish rival Meda on the condition the newly-merged company sheds businesses in around a dozen European countries. Mylan offered to divest either its own or Meda's local... More...>>
07/20/201611:03AMPRNUSMylan Launches Generic Crestor® Tablets
Mylan Launches Generic Crestor® Tablets PR Newswire HERTFORDSHIRE, England and PITTSBURGH, July 20, 2016 HERTFORDSHIRE, England and PITTSBURGH, July 20, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Rosuvastatin Calcium Tablets, 5 mg, 10 mg, 20 mg and 40 mg, which is a generic... More...>>
07/20/20169:20AMDJNAbbott Labs Profit Tops Views
Abbott Laboratories Inc., in the middle of its tie-up with St. Jude Medical Inc., said Wednesday that earnings declined 22% from a year earlier amid higher expenses. However, adjusted profit beat analysts expectations by 2 cents and revenue climbed, helped by recent product launches. Shares rose 2.9% to $43 in recent premarket... More...>>
07/15/20167:30AMPRNUSMarket Updates on Drugs - Generic Equities -- Mylan, Horizon Pharma, Allergan, and Diplomat Pharmacy
Market Updates on Drugs - Generic Equities -- Mylan, Horizon Pharma, Allergan, and Diplomat Pharmacy PR Newswire NEW YORK, July 15, 2016 NEW YORK, July 15, 2016 /PRNewswire/ -- On Thursday, July 14, 2016, the NASDAQ Composite ended the trading session at 5,034.06, up 0.57%; the Dow Jones Industrial Average edged 0.73... More...>>
07/11/20167:30AMPRNUSMylan Launches Generic Temodar® Capsules
Mylan Launches Generic Temodar® Capsules PR Newswire HERTFORDSHIRE, England and PITTSBURGH, July 11, 2016 HERTFORDSHIRE, England and PITTSBURGH, July 11, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Temozolomide Capsules, 5 mg, 20 mg, 100 mg, 140 mg, 180 mg and 250 mg, which... More...>>
07/07/201610:47AMPRNUSMylan to Report Second Quarter 2016 Financial Results on August 9, 2016
Mylan to Report Second Quarter 2016 Financial Results on August 9, 2016 PR Newswire HERTFORDSHIRE, England and PITTSBURGH, July 7, 2016 HERTFORDSHIRE, England and PITTSBURGH, July 7, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that it will host a conference call and live webcast, on Tuesday, August... More...>>
07/06/20167:30AMPRNUSMylan Launches Generic Fenoglide® Tablets
Mylan Launches Generic Fenoglide® Tablets PR Newswire HERTFORDSHIRE, England and PITTSBURGH, July 6, 2016 HERTFORDSHIRE, England and PITTSBURGH, July 6, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Fenofibrate Tablets USP, 40 mg and 120 mg, which is a generic version of Santarus's... More...>>
06/24/201611:44AMPRNUSMylan Launches Generic Avodart® Capsules
Mylan Launches Generic Avodart® Capsules PR Newswire HERTFORDSHIRE, England and PITTSBURGH, June 24, 2016 HERTFORDSHIRE, England and PITTSBURGH, June 24, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Dutasteride Capsules, 0.5 mg, the generic version of GlaxoSmithKline's Avodart®... More...>>
06/23/201611:22AMPRNUSMylan Donates €1 Million to the Princess Máxima Center for Pediatric Oncology
Mylan Donates €1 Million to the Princess Máxima Center for Pediatric Oncology PR Newswire HERTFORDSHIRE, England, PITTSBURGH, and UTRECHT, Netherlands, June 23, 2016 HERTFORDSHIRE, England, PITTSBURGH, and UTRECHT, Netherlands, June 23, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), one of the world's leading... More...>>
06/20/20169:54AMPRNUSAttorney General Rejects VEB's Request Regarding Mylan Shareholder Approval of Meda Transaction
Attorney General Rejects VEB's Request Regarding Mylan Shareholder Approval of Meda Transaction PR Newswire HERTFORDSHIRE, England, and PITTSBURGH, June 20, 2016 HERTFORDSHIRE, England, and PITTSBURGH, June 20, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today confirmed that the Attorney General of the Netherlands... More...>>
06/17/20168:00AMPRNUSDrugs - Generic Stocks Technical Data - Allergan, Mylan, Horizon Pharma, and Celator Pharma
Drugs - Generic Stocks Technical Data - Allergan, Mylan, Horizon Pharma, and Celator Pharma PR Newswire NEW YORK, June 17, 2016 NEW YORK, June 17, 2016 /PRNewswire/ -- On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial Average advanced 0.53% to finish... More...>>
06/16/20164:35PMPRNUSMylan to Commence Meda Offer on June 17
Mylan to Commence Meda Offer on June 17 PR Newswire HERTFORDSHIRE, England and PITTSBURGH, June 16, 2016 Mylan's Offer Document Approved and Published HERTFORDSHIRE, England and PITTSBURGH, June 16, 2016 /PRNewswire/ -- The Offer is not being made, and this press release may not be distributed, directly or indirectly... More...>>
06/16/20164:35PMPRNUSMylan to Commence Meda Offer on June 17
Mylan to Commence Meda Offer on June 17 Mylan's Offer Document Approved and Published PR Newswire HERTFORDSHIRE, England, and PITTSBURGH, June 16, 2016 HERTFORDSHIRE, England, and PITTSBURGH, June 16, 2016 /PRNewswire/ -- The Offer is not being made, and this press release may not be distributed, directly or indirectly... More...>>
06/15/20161:47PMPRNUSMylan Completes Acquisition of Renaissance's Leading Topicals-Focused Specialty and Generics Business
Mylan Completes Acquisition of Renaissance's Leading Topicals-Focused Specialty and Generics Business PR Newswire HERTFORDSHIRE, England and PITTSBURGH, June 15, 2016 HERTFORDSHIRE, England and PITTSBURGH, June 15, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that it has successfully completed the... More...>>
06/03/20166:00PMDJNStudy Finds Mylan's 'Biosimilar' Drug Comparable to Roche Cancer Medicine
CHICAGO—Researchers said a drug being developed by Mylan Pharmaceuticals Inc. proved comparable to Roche Holding AG's Herceptin in a clinical trial, a new milestone in the effort to bring cheaper versions of some of biotechnology's best-known cancer drugs to the market. In a study involving a total of 500... More...>>
06/03/20162:00PMPRNUSMylan and Biocon to Present Phase 3 Trastuzumab Biosimilar Data at the American Society of Clinical Oncology (ASCO) Annual Me...
Mylan and Biocon to Present Phase 3 Trastuzumab Biosimilar Data at the American Society of Clinical Oncology (ASCO) Annual Meeting HERITAGE Study Shows Comparable Efficacy, Safety and Immunogenicity to Branded Trastuzumab in HER2-Positive Metastatic Breast Cancer Patients PR Newswire HERTFORDSHIRE, England, PITTSBURGH... More...>>
06/03/201610:56AMPRNUSMylan Launches Generic Cleocin® Solution
Mylan Launches Generic Cleocin® Solution PR Newswire HERTFORDSHIRE, England and PITTSBURGH, June 3, 2016 HERTFORDSHIRE, England and PITTSBURGH, June 3, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Clindamycin Palmitate Hydrochloride for Oral Solution USP, 75 mg/5 mL, which is... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V:us D:20160727 03:45:06